Tirzepatide and the risk of artery-clogging heart events in a large population study

Adding tirzepatide to standard care treatment may reduce major adverse cardiovascular events (MACE).

• Tirzepatide is associated with a potential decrease in the incidence of MACE.
• The magnitude of this reduction is not yet quantified.
• Observations are based on estimates rather than direct clinical outcomes.
• Further research is needed to confirm these potential benefits in clinical practice.

Simplified